Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Corticosteroids; Hydrocortisone; Triamcinolone
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms BREEZE-AD7
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 01 May 2023 Results assessing the long-term efficacy of baricitinib combined with topical corticosteroids (TCS) in adult patients from a Phase 3 study, BREEZE-AD7 (NCT03733301), enrolled in ongoing extension study, BREEZE-AD3 (NCT03334435), published in the Journal of the European Academy of Dermatology and Venereology.
- 01 Jul 2021 Results of an analysis assessing the efficacy of baricitinib plus topical corticosteroids using functional measures of HRQoL, work productivity and life activities, symptom impact and treatment benefit in adults with moderate-to-severe AD with previous inadequate response to topical corticosteroids published in the Journal of the European Academy of Dermatology and Venereology
- 23 Apr 2021 According to an Eli Lilly media release, these results are being presented virtually at the American Academy of Dermatology's Virtual Meeting Experience (AAD VMX), April 23-25, 2021.